论文部分内容阅读
抗凝血酶Ⅱ的变化在血栓栓塞性疾病中具有重要作用,先天性抗凝血酶Ⅱ缺乏时,引起反复静脉血栓形成。为了确定肝素对抗凝血酶Ⅱ的影响,作者比较皮下注射肝素治疗前后抗凝血酶Ⅱ的浓度,以估计肝素治疗的抗凝血酶Ⅱ变化。在肝素治疗前,用免疫扩散法测定15例新近无血栓形成表现患者的血浆如血清抗凝血酶Ⅱ,平均浓度与对照组无区别。注肝素后6小时,11例出现抗凝作用,表现为凝血酶时间延长,血肝素含量等于或超过
Changes in antithrombin Ⅱ in thromboembolic diseases play an important role, congenital antithrombin Ⅱ deficiency, causing repeated venous thrombosis. To determine the effect of heparin on antithrombin II, we compared antithrombin II concentrations before and after subcutaneous injection of heparin to estimate the change in antithrombin II treated with heparin. Prior to heparin treatment, 15 patients with newly developed thrombotic manifestations of plasma antithrombin II, such as serum antithrombin II, were assayed by immunodiffusion with no difference in mean concentrations from those in the control group. Six hours after injection of heparin, anticoagulation occurred in 11 patients, which showed prolonged thrombin time and blood heparin content equal to or more than